SCHEMBL3015002

SCHEMBL3015002

Cc1cccc(-c2csc(N3CCN(S(=O)(=O)c4ccc(Cl)cc4Cl)CC3)n2)c1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.52
MAPK1 P28482 5/20 0.52
MEN1 O00255 4/20 0.52
KMT2A Q03164 4/20 0.52
MAPT P10636 9/20 0.52
USP2 O75604 1/20 0.52
RECQL P46063 1/20 0.52
HSD17B10 Q99714 1/20 0.52
ALDH1A1 P00352 5/20 0.50
SMN1; SMN2 Q16637 4/20 0.50
RAB9A P51151 2/20 0.48
L3MBTL1 Q9Y468 1/20 0.47
NPSR1 Q6W5P4 3/20 0.45
GAA P10253 2/20 0.45
TSHR P16473 1/20 0.44
AR P10275 1/20 0.43
HSD11B1 P28845 1/20 0.43
HTT P42858 1/20 0.43
NPC1 O15118 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3013300 0.92 MEN1 (0.52) LMNAMAPK1MEN1KMT2AMAPT
SCHEMBL3014049 0.91 SMN1; SMN2 (0.49) LMNAMAPK1MEN1KMT2AMAPT
SCHEMBL3019326 0.90 MAPT (0.59) LMNAMAPK1MEN1KMT2AMAPT
SCHEMBL3016064 0.90 MAPT (0.50) LMNAMAPK1MEN1KMT2AMAPT
SCHEMBL3017906 0.90 MAPT (0.56) LMNAMAPK1MEN1KMT2AMAPT
SCHEMBL3017021 0.89 SMN1; SMN2 (0.54) LMNAMAPK1MEN1KMT2AMAPT
SCHEMBL3009764 0.89 MAPK1 (0.63) LMNAMAPK1MEN1KMT2AMAPT
SCHEMBL3013564 0.88 MAPT (0.50) LMNAMAPK1MEN1KMT2AMAPT
SCHEMBL3006873 0.88 LMNA (0.52) LMNAMAPK1MEN1KMT2AMAPT
SCHEMBL3013695 0.88 MAPT (0.63) LMNAMAPK1MEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA LMNA 80/4885MAPK1 2767/4885MEN1 454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.